Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1

Lancet

Volumn 359, Issue 9318, 2002, Pages 1667-1668

  Paton, Nicholas I ^a   Aboulhab, Jamila ^a   Karim, Fatimah ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; HYDROXYCHLOROQUINE; HYDROXYUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECONOMIC ASPECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

EID: 0037062206     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08557-4     Document Type: Article

References (5)

1. Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes
2. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1
3. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea
4. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
5. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection